ELEDON PHARMACEUTICALS INC (ELDN)
US28617K1016 - Common Stock
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results...
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants...
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of Regimen Following Islet Transplantation...
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference...
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Enrollment Completed Four Months Ahead of Schedule
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients
Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplants...
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
ELDN stock results show that Eledon Pharma missed analyst estimates for earnings per share the second quarter of 2024.
ELDN Stock Earnings: Eledon Pharma Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ:ELDN) just reported results for the second quarter of 202...
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results
Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results...
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
80 Participants (Two-thirds of Projected Recruitment) Enrolled
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection
Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection...
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism
Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism...
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
You don’t want to overlook these three penny stocks filled to the brim with the potential to make huge leaps in their respective markets.
3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024
Although the very idea of millionaire-maker penny stocks implies incredibly high risks, if all cylinders fire, these companies could fly.
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation...
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ:ELDN) just reported results for the first quarter of 2024...
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q1 2024
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results...
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant Congress
Eledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at ATC 2024...
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection...
Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
ELDN stock results show that Eledon Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.
ELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eledon Pharma (NASDAQ:ELDN) just reported results for the fourth quarter of 202...
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results ...